ES-SCLC
-
Iftinitamab Deruxtecan Shows Clinically Meaningful Response in Extensive-Stage SCLC Patients: IDeate-Lung01 Phase 2 Trial Results
Daiichi Sankyo and Merck announced positive Phase 2 IDeate-Lung01 trial results for ifinatamab deruxtecan (I-DXd) in previously treated extensive-stage small cell lung cancer (ES-SCLC). I-DXd demonstrated a 48.2% objective response rate (ORR) in patients who had progressed after platinum-based chemotherapy, with a median duration of response of 5.3 months. Notably, a second-line subset achieved a 56.3% ORR. Discussions with regulatory authorities are underway. The safety profile was consistent with prior observations.
